GeoVax Labs(GOVX) - 2025 Q3 - Quarterly Results

Financial Performance - Net loss for Q3 2025 was $6,318,914, or $0.31 per share, compared to a net loss of $5,815,468, or $0.91 per share in Q3 2024[9] - Revenue for Q3 2025 was $0, down from $2,789,484 in Q3 2024, with total government contract revenues for the nine-month period at $2,489,145, compared to $3,090,161 in 2024[10] - The company reported a total net loss of $17,046,348 for the nine-month period ended September 30, 2025, compared to $16,729,642 in 2024[9] Expenses and Liabilities - Research and development expenses decreased to $5,043,504 in Q3 2025 from $7,402,884 in Q3 2024, primarily due to the termination of the BARDA contract[13] - Cash balances as of September 30, 2025, were $5,008,997, down from $5,506,941 at December 31, 2024[15] - The total liabilities decreased to $1,824,000 as of September 30, 2025, from $3,107,000 at December 31, 2024[27] Vaccine Programs and Developments - The GEO-CM04S1 COVID-19 vaccine program showed robust immune responses in CLL patients, achieving its immunogenicity target and prompting the discontinuation of the comparator mRNA arm[12] - GeoVax is expanding its Gedeptin® oncology program into new solid tumor indications, with plans for a Phase 2 trial in head and neck cancer targeted for 2H 2026[12] - The company is advancing its GEO-MVA vaccine in response to the global Mpox public health emergency, supported by favorable scientific advice from the EMA[6] - GeoVax's multi-antigen vaccine platforms align with U.S. policy priorities for pandemic preparedness and domestic manufacturing[12]